Clinical trial
Prospective Multicentre Comparative Randomized Double Blind Placebo Controlled Study of Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After Having the Novel Coronavirus Infection (COVID-19)
NCT05689827 is registered in ClinicalTrials.gov with Promomed, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Multicentre Comparative Randomized Double Blind Placebo Controlled Study of Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After Having the Novel Coronavirus Infection (COVID-19)
- Lead sponsor
- Promomed, LLC
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 5, 2022
- Completion date
- November 10, 2022
- Enrollment
- 160 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.